Rapid simultaneous determination of voriconazole and its N-oxide in human plasma using an isocratic high-performance liquid chromatography method and its clinical application

Clinical Biochemistry

Volumn 45, Issue 1-2, 2012, Pages 134-138

  Yamada, Takahiro ^a   Mino, Yasuaki ^a   Yagi, Tatsuya ^a   Naito, Takafumi ^a   Kawakami, Junichi ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

HPLC UV; Human plasma; Isocratic elution; Voriconazole; Voriconazole N oxide

Indexed keywords

ACETONITRILE; BLOOD EXTRACT; PAPAVERINE; UNCLASSIFIED DRUG; VORICONAZOLE; VORICONAZOLE N OXIDE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG SELECTIVITY; DRUG STABILITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; MALE; MYCOSIS; PRIORITY JOURNAL;

ACETONITRILES; ADULT; AGED; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; HUMANS; MALE; MIDDLE AGED; MODELS, CHEMICAL; OXIDES; PLASMA; PYRIMIDINES; REPRODUCIBILITY OF RESULTS; TIME FACTORS; TRIAZOLES; ULTRAVIOLET RAYS;

EID: 84855297883     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2011.11.004     Document Type: Article

References (19)

1. Walsh T.J., Anaissie E.J., Denning D.W., Herbrecht R., Kontoyiannis D.P., Marr K.A., et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008, 46:327-360.
2. Steinbach W.J., Stevens D.A. Review of newer antifungal and immunomodulatory strategies for invasive aspergillosis. Clin Infect Dis 2003, 37:S157-S187.
3. Ueda K., Nannya Y., Kumano K., Hangaishi A., Takahashi T., Imai Y., et al. Monitoring trough concentration of voriconazole is important to ensure successful antifungal therapy and to avoid hepatic damage in patients with hematological disorders. Int J Hematol 2009, 89:592-599.
4. Tan K., Brayshaw N., Tomaszewski K., Troke P., Wood N. Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities. J Clin Pharmacol 2006, 46:235-243.
5. Pascual A.T., Calandra T., Bolay S., Buclin T., Bille J., Marchetti O. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 2008, 46:201-211.
6. Dodds Ashley E.S., Lewis R., Lewis J.S., Martin C., Andes D. Pharmacology of systemic antifungal agents. Clin Infect Dis 2006, 43:S28-S39.
7. Purkins L., Wood N., Ghahramani P., Greenhalgh K., Allen M.J., Kleinermans D. Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens. Antimicrob Agents Chemother 2002, 46:2546-2553.
8. Hyland R., Jones B.C., Smith D.A. Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole. Drug Metab Dispos 2003, 31:540-547.
9. Yanni S.B., Annaert P.P., Augustijns P., Bridges A., Gao Y., Benjamin D.K., et al. Role of flavin-containing monooxygenase in oxidative metabolism of voriconazole by human liver microsomes. Drug Metab Dispos 2008, 36:1119-1125.
10. Jeu L., Piacenti F.J., Lyakhovetskiy A.G., Fung HB H.B. Voriconazole. Clin Ther 2003, 25:1321-1381.
11. Smith J., Safdar N., Knasinski V., Simmons W., Bhavnani S.M., Ambrose P.G., et al. Voriconazole therapeutic drug monitoring. Antimicrob Agents Chemother 2006, 50:1570-1572.
12. Eiden C., Mathieu O., Peyrie're H., Hillaire-Buys D., Cociglio M. Simultaneous quantification of voriconazole and its N-Oxide metabolite in human plasma by an easy and rapid isocratic LC method with UV detection. Chromatographia 2008, 67:275-280.
13. Roffey S.J., Cole S., Comby P., Gibson D., Jezequel S.G., Nedderman A.N.R., et al. The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog, and human. Drug Metab Dispos 2003, 31:731-741.
14. Khoschsorur G., Fruehwirth F., Zelzer S. Isocratic high-performance liquid chromatographic method with ultraviolet detection for simultaneous determination of levels of voriconazole and itraconazole and its hydroxy metabolite in human serum. Antimicrob Agents Chemother 2005, 49:3569-3571.
15. Vogeser M., Schiel X., Spöhrer U. Quantification of voriconazole in plasma by liquid chromatography-tandem mass spectrometry. Clin Chem Lab Med 2005, 43:730-734.
16. Wenk M., Droll A., Krähenbühl S. Fast and reliable determination of the antifungal drug voriconazole in plasma using monolithic silica rod liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci 2006, 832:313-316.
17. Center for Drug Evaluation and Research, U.S. Food and Drug Administration. Guidance for Industry Bioanalytical Method Validation May, 2001, Available at, Accessed July 1, 2011. http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm064964.htm.
18. Eiden C., Cociglio M., Hillaire-Buys D., Eymard-Duvernay S., Ceballos P., Fegueux N., et al. Pharmacokinetic variability of voriconazole and N-oxide voriconazole measured as therapeutic drug monitoring. Xenobiotica 2010, 40:701-706.
19. Pavlos M., Sophia L.M., Penelope E., Stratos D., Effimia E., Dimitris P., et al. Monitoring plasma voriconazole levels following intravenous administration in critically ill patients: an observational study. Int J Antimicrob Agents 2010, 35:468-472.